AUS
NZ
UK
CA
USA
IND
Highlights
- PharmAla Biotech partners with Merhavim Mental Health Centre to support MDMA-assisted PTSD therapy.
- The trial will focus on MDMA’s efficacy for PTSD related to early sexual trauma and adulthood trauma.
- PharmAla will provide LaNeo™ MDMA for the trial on a zero-cost basis in exchange for the data.
PharmAla Biotech Holdings Inc. (CSE:MDMA), a biotechnology company at the forefront of developing LaNeo™ MDMA and novel MDMA derivatives, has entered into an agreement with the Merhavim Mental Health Centre of Beer Yaakov, Israel. This collaboration will support a clinical trial titled “MDMA Assisted Psychotherapy for PTSD of Early Sexual Trauma Compared to All Trauma in Adulthood.” The results of this trial will be licensed to PharmAla for regulatory and commercial purposes, in exchange for the clinical trial material, which PharmAla will supply on a zero-cost basis.
Innovative Clinical Trial Focused on MDMA for PTSD Treatment
The clinical trial aims to explore the effectiveness of MDMA-assisted psychotherapy in treating Post-Traumatic Stress Disorder (PTSD) caused by early sexual trauma, compared to PTSD caused by trauma experienced in adulthood. The collaboration is part of PharmAla’s continued commitment to expanding the clinical applications of MDMA, building on the growing body of evidence supporting MDMA’s therapeutic potential for mental health conditions like PTSD.
PharmAla’s LaNeo™ MDMA Clinical Research Materials will be provided to Merhavim, pending the necessary regulatory approvals. This trial represents a significant step forward in understanding how MDMA can be utilized to treat trauma experienced at different stages of life. This study is expected to offer valuable insights into how MDMA-assisted therapy can be tailored to different patient needs, expanding on existing research that has already demonstrated MDMA’s efficacy in treating PTSD.
Collaboration with MAPS Israel and Potential Global Impact
In addition to Merhavim, PharmAla will be collaborating with MAPS Israel, a non-profit organization dedicated to the development of psychedelic research and education. MAPS Israel's involvement ensures that the trial will be conducted under the highest ethical and scientific standards. The partnership highlights PharmAla’s ongoing dedication to advancing the understanding of psychedelics in mental health care, particularly in addressing complex and pervasive conditions like PTSD.
PharmAla’s CEO, Nicholas Kadysh, expressed optimism about the trial's potential to make a difference, stating, “The recent announcement of a cease-fire in the Gaza conflict means that now is the time to work towards healing. We look forward to supporting Merhavim in their clinical trial, which we believe will help patients in Israel, and ultimately worldwide.” He added, “To the best of our knowledge, this will be the first trial to explicitly examine MDMA’s efficacy in the treatment of recent versus aged trauma.”
Supporting Clinical Research and Future Collaborations
PharmAla is committed to advancing the psychedelic research space and providing support to researchers conducting clinical trials with MDMA. Researchers can access a tool on PharmAla’s website (https://pharmala.ca/clinical-trials), which offers direct access to drug product quality information for their studies. PharmAla aims to provide rapid support to clinical trial registrants, assisting with the conversion of their Institutional Review Board (IRB) approvals and clinical trial registrations to the LaNeo MDMA Chemistry, Manufacturing, and Control package.
With this agreement, PharmAla is not only supporting groundbreaking research but is also positioning itself as a key player in the rapidly growing field of psychedelic therapy. The results of the Merhavim trial, along with other collaborative research efforts, will contribute to the development of more targeted and effective treatments for PTSD, offering hope to patients worldwide.
